Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Intrexon Corp (XON)

Intrexon Corp (XON)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 756,476
  • Shares Outstanding, K 162,683
  • Annual Sales, $ 160,570 K
  • Annual Income, $ -509,340 K
  • 60-Month Beta 2.26
  • Price/Sales 5.49
  • Price/Cash Flow N/A
  • Price/Book 3.30
Trade XON with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.94
  • Most Recent Earnings -0.35 on 11/12/19
  • Next Earnings Date 02/27/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.162 on 06/09/15
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.25
  • Number of Estimates 3
  • High Estimate -0.23
  • Low Estimate -0.27
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.62 +0.65%
on 01/31/20
7.28 -36.13%
on 01/14/20
-0.83 (-15.15%)
since 12/31/19
3-Month
4.62 +0.65%
on 01/31/20
7.28 -36.13%
on 01/14/20
-0.43 (-8.46%)
since 10/31/19
52-Week
3.95 +17.72%
on 04/18/19
8.77 -46.98%
on 06/18/19
-3.05 (-39.61%)
since 01/30/19

Most Recent Stories

More News
AavantiBio Adds Veteran Life Sciences Executive Douglas J. Swirsky as Chief Financial Officer and Treasurer

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Douglas J. Swirsky as Chief Financial Officer and Treasurer...

XON : 4.65 (-4.12%)
RNN : 5.24 (+0.19%)
OCUP : 10.05 (-3.37%)
CLRB : 1.8600 (-7.46%)
NRBO : 4.40 (-5.98%)
At 21.9% CAGR, Synthetic Biology Market Size Expected to Reach 34.51 Bn by 2026 Says Brandessence Market Research

The global demand for synthetic biology market in terms of revenue was estimated to be USD 7.54 Billion in 2019 and is expected to reach USD 34.51 Billion in 2026, growing at a CAGR of 21.9% from 2020...

AMRS : 17.43 (-12.63%)
CDXS : 20.86 (-7.70%)
ERRFY : 14.4000 (-27.09%)
GNNSF : 1.8500 (-2.63%)
XON : 4.65 (-4.12%)
MKKGY : 31.9600 (-2.29%)
NVZMF : 62.0212 (-1.87%)
Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

, /PRNewswire/ --  (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 17,250,000 shares of its common stock at a public...

XON : 4.65 (-4.12%)
PGEN : 8.41 (-1.98%)
Pioneer Natural Resources: An Oil and Gas Stock Worth Buying

Pioneer Natural Resources (PXD) is well positioned to benefit from the recovery of the global economy because the demand for oil and natural gas will rise with the resumption of industrial operations....

PXD : 154.16 (+2.94%)
XON : 4.65 (-4.12%)
CVX : 103.59 (+1.12%)
COP : 53.66 (+2.64%)
Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference

, /PRNewswire/ -- (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced , PhD, President...

JPM : 152.91 (+1.93%)
XON : 4.65 (-4.12%)
PGEN : 8.41 (-1.98%)
Zika Virus Vaccines Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The research report titled Zika Virus Vaccines offers comprehensive information on key driving factors, pricing analysis, market growth trends, brand positioning, competitive landscape, product usage and...

CERS : 6.28 (-2.79%)
GSK : 34.24 (+0.44%)
IMV.TO : 4.20 (-0.94%)
INO : 9.56 (-4.59%)
XON : 4.65 (-4.12%)
NLNK : 0.8900 (-12.75%)
TKPYY : 16.5900 (-0.90%)
Precigen Inc. f/k/a/ Intrexon Corporation: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Investors with losses are encouraged to contact the firm before December 4, 2020; click here to submit trade information

XON : 4.65 (-4.12%)
PGEN : 8.41 (-1.98%)
PGEN INVESTOR DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation

, /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been...

PGEN : 8.41 (-1.98%)
XON : 4.65 (-4.12%)
Scott+Scott Attorneys at Law LLP Alerts Investors to December 4 Lead Plaintiff Deadline in Securities Class Actions Against Precigen, Inc. (PGEN)

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, reminds investors that class action lawsuits are pending against Precigen, Inc. ("Precigen"...

PGEN : 8.41 (-1.98%)
XON : 4.65 (-4.12%)
Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results

, /PRNewswire/ -- (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter and...

XON : 4.65 (-4.12%)
PGEN : 8.41 (-1.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Intrexon Corporation is a biotechnology company. It provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. Its technologies include...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 4.94
1st Resistance Point 4.79
Last Price 4.65
1st Support Level 4.56
2nd Support Level 4.48
3rd Support Level N/A

See More

52-Week High 8.77
Fibonacci 61.8% 6.93
Fibonacci 50% 6.36
Fibonacci 38.2% 5.79
Last Price 4.65
52-Week Low 3.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar